Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study.
Saved in:
| Title: | Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study. |
|---|---|
| Authors: | Rinderknecht E; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Urology, University Hospital Augsburg, Augsburg, Germany. Electronic address: emily.rinderknecht@uk-augsburg.de., Bielstein G; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany., Cathomas R; Department of Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland., Schlack K; Department of Urology, University Hospital Münster, Münster, Germany., Bastian JLD; Department of Urology and Pediatric Urology, Saarland University, Homburg, Germany., Darr C; Department of Urology, West German Cancer Center, University of Duisburg, German Cancer Consortium, University Hospital Essen, Essen, Germany., Unland-Gies D; Department of Urology, University Hospital, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany., Kappler P; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Paffenholz P; Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne, Cologne Germany; Center for Integrated Oncology (CIO) Köln-Bonn, Cologne, Germany., Richter J; Department of Medical Oncology and Internal Medicine VI, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany., Müller M; Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany., Seitz AK; Department of Urology and Pediatric Urology, University Hospital Würzburg, Würzburg, Germany., Steinestel J; Department of Urology, University Hospital Augsburg, Augsburg, Germany., Heidegger I; Department of Urology, Medical University Innsbruck, Innsbruck, Austria., Burger M; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany., Breyer J; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany., Schnabel MJ; Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany. |
| Source: | Urologic oncology [Urol Oncol] 2026 Apr; Vol. 44 (4), pp. 111028. Date of Electronic Publication: 2026 Feb 20. |
| Publication Type: | Journal Article; Multicenter Study; Comparative Study |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 9805460 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2496 (Electronic) Linking ISSN: 10781439 NLM ISO Abbreviation: Urol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
